Evolus, Inc. - Common Stock (EOLS)

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full-year ended December 31, 2024.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in fireside chats and investor meetings at upcoming investor conferences in Miami, FL:

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on Thursday, February 27, 2025.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection. These approvals mark Evolus’ entry into the U.S. HA dermal filler market and solidifies the company’s position as a multi-product innovator in aesthetics, expanding Evolus’ total addressable market by 78% to approximately $6 billion1.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 26,897 shares of Evolus and an aggregate of 99,826 restricted stock units (RSUs) of the company’s common stock to 34 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of February 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

Evolus, Inc. (NASDAQEOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company’s 2024 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2024, which is anticipated to occur in early March 2025.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the company’s common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of January 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November non-qualified stock options to purchase an aggregate of 9,872 shares of Evolus and an aggregate of 16,596 restricted stock units (RSUs) of the company’s common stock to 9 newly hired non-executive employees of the company (the “November Grants”). The Company also is reporting the grant in December non-qualified stock options to purchase an aggregate of 6,034 shares of Evolus and an aggregate of 22,295 RSUs of the company’s common stock to 11 newly hired non-executive employees of the company (the “December Grants”). The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of November 7, 2024 for the November Grants and December 7, 2024 for the December Grants, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced “esteem”), branded as Evolysse™ in the U.S. market. This certification marks a key regulatory milestone for Evolus, enabling it to commercially enter the dermal filler segment and doubling its addressable market outside the U.S. to $1.8 billion1.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau® redemption in its Evolus Rewards™ patient loyalty program.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,251 shares of Evolus and an aggregate of 31,049 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-executive employees of the company.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company’s common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant date of September 12, 2024, and a vesting commencement date of September 7, 2024, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasdaq closing bell on Friday, September 13, 2024.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July an aggregate of 46,363 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-executive employees of the company (the “July Grants”). The Company also is reporting the grant in August of an aggregate of 35,921 RSUs and non-qualified stock options to purchase an aggregate of 18,097 shares of Evolus to 10 newly hired non-executive employees of the Company (the “August Grants”). The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of July 7, 2023 for the July Grants and August 7, 2023 for the August Grants, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the second quarter ended June 30, 2024, and provided a business update.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast.

Evolus, Inc. (NASDAQEOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of Nuceiva® (prabotulinumtoxinA).

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sandra Beaver, CFO, will present at the following investor conference.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus’ Compensation Committee.

Evolus, Inc. (NASDAQEOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF).